- 1 Title: Vaccination saves lives: How do patients with chronic diseases and severe COVID-19 fare? Analysis
- 2 from India's National Clinical registry for COVID-19
- 3 Author List

4 5 <sup>¶</sup>Aparna Mukherjee, PhD<sup>1</sup>; <sup>¶</sup>Gunjan Kumar, MD<sup>1</sup>; Alka Turuk, MD<sup>1</sup>; Ashish Bhalla, MD<sup>2</sup>; Thrilok 6 Chander Bingi, MD<sup>3</sup> Pankaj Bhardwaj, MD<sup>4</sup>; Tridip Dutta Baruah, MS<sup>5</sup>; Subhasis Mukherjee, MD<sup>6</sup>; Arunansu Talukdar, PhD<sup>7</sup>; Yogiraj Ray, MD<sup>8</sup>, Mary John, MD<sup>9</sup>, Janakkumar R Khambholja, MD<sup>10</sup>; Amit 7 8 H. Patel, MD<sup>11</sup>; Sourin Bhuniya, MD<sup>12</sup>; Rajnish Joshi, MD<sup>13</sup>, Geetha R Menon, PhD<sup>14</sup>; Damodar Sahu,

- 9 PhD14; Vishnu Vardhan Rao, PhD14; Balram Bhargava, DM1; \*Samiran Panda, MD1
- 10 11

12 And the NCRC Study team

- Puspendra Mishra, MCA<sup>14</sup>; Yashmin Panchal, PGDISAD<sup>14</sup>; Lokesh Kumar Sharma, PhD<sup>1</sup>; Anup Agarwal, 13 MBBS<sup>15</sup>; GD Puri, MD<sup>2</sup>; Vikas Suri, MD<sup>2</sup>; Karan Singla, MD<sup>2</sup>; Rajarao Mesipogu, MD<sup>3</sup>; Vinaya Sekhar 14 15 Aedula, MD<sup>3</sup>; Mohammed Ayaz Mohiuddin, MD<sup>3</sup>; Deepak Kumar, MD<sup>4</sup>; Suman Saurabh, MD<sup>4</sup>; Sanjeev Misra, MCh<sup>4</sup>; Pankaj Kumar Kannauje, MD<sup>5</sup>; Ajit Kumar, MD<sup>5</sup>; Arvind Shukla, PhD<sup>5</sup>; Amitava Pal, MD<sup>6</sup>, 16 Shreetama Chakraborty, MSc<sup>6</sup>; Moumita Dutta, MSc<sup>6</sup>; Tanushree Mondal, MD<sup>7</sup>; Sarmistha Chakravorty, 17 18 MSc<sup>7</sup>; Boudhyan Bhattacharjee, MD<sup>7</sup>; Shekhar Ranjan Paul, DTCD<sup>8</sup>; Debojyoti Majumder, MD<sup>8</sup>; 19 Subhranga Chatterjee, MBBS<sup>8</sup>; Abin Abraham, MD<sup>9</sup>; Divya Varghese, MD<sup>9</sup>; Maria Thomas, MD<sup>9</sup>; Nitesh 20 shah, MD<sup>11</sup>; Minesh Patel, MD<sup>11</sup>, Surabhi Madan, MD<sup>11</sup>; Anita Desai, PhD<sup>16</sup>; Kala Yadhav M L, MD<sup>17</sup>; Madhumathi. R, MD<sup>17</sup>; Chetna GS, MD<sup>17</sup>; U K Ojha, MD<sup>18</sup>; Ravi Ranjan Jha<sup>18</sup>, Avinash Kumar, MD<sup>18</sup>; 21 Ashish Pathak, PhD<sup>19</sup>; Ashish Sharma, MD<sup>19</sup>; Manju Purohit, MD<sup>19</sup>; Lisa Sarangi, MD<sup>20</sup>; Mahesh Rath, 22 MD<sup>20</sup>; Arti D. Shah, DNB<sup>21</sup>; Lavlesh Kumar, MD<sup>21</sup>; Princee Patel, MBBS<sup>21</sup>; Naveen Dulhani, MD<sup>22</sup>, 23 24 Simmi Dube, MD<sup>23</sup>; Jyotsna Shrivastava, MD<sup>23</sup>; Arvind Mittal, MD<sup>23</sup>; Lipilekha Patnaik, MD<sup>24</sup>; Jagdish 25 Prasad Sahoo, DM<sup>24</sup>; Sumita sharma<sup>24</sup>; V K Katyal, MD, FACC<sup>25</sup>; Ashima Katyal, MD<sup>25</sup>; Nidhi Yadav, MD<sup>25</sup>; Rashmi Upadhyay, MD<sup>26</sup>; Saurabh Srivastava, MD<sup>26</sup>; Anurag Srivastava, MD<sup>26</sup>; Nilay N.Suthar, MD<sup>10</sup>; Nehal M. Shah, MD<sup>10</sup>; Kruti Rajvansh, MD<sup>10</sup>; Hemang Purohit, MSc<sup>10</sup>; Prasanta Raghab 26 27 Mohapatra, MD<sup>12</sup>; Manoj Kumar Panigrahi, MD<sup>12</sup>; Saurabh Saigal, MD, EDIC<sup>13</sup>; Alkesh Khurana, MD<sup>13</sup>; 28 29 Manisha Panchal, MD<sup>27</sup>; Mayank Anderpa, MD<sup>27</sup>; Dhruv Patel, MBBS<sup>27</sup>; Veeresh Salgar, MD<sup>28</sup>; Santosh Algur, MBBS<sup>28</sup>; Ratnamala Choudhury, MD<sup>29</sup>; Mangala Rao. MD<sup>29</sup>; Nithya D, MSc<sup>29</sup>; Bal Kishan Gupta, 30 MD<sup>30</sup>; Bhuvanesh Kumar, MD<sup>30</sup>; Jigyasa Gupta, MBBS<sup>30</sup>; Sudhir Bhandari, MD<sup>31</sup>; Abhishek Agrawal, 31 32 MD<sup>31</sup>; Mohammad Shameem, MD, FRCP<sup>32</sup>; Nazish Fatima, MD<sup>32</sup>; Star Pala, MD<sup>33</sup>; Vijay Nongpiur, DM<sup>33</sup>; Soumyadip Chatterji, DM<sup>34</sup>; Sudipta Mukherjee, FNB<sup>34</sup>; Sachin K Shivnitwar, MD<sup>35</sup>; Srikanth 33 Tripathy, MD<sup>35</sup>; Prajakta Lokhande, MPH<sup>35</sup>; Himanshu Dandu, MD<sup>36</sup>; Amit Gupta, MD<sup>36</sup>; Vivek Kumar, 34 35 MD<sup>36</sup>; Nikita Sharma, MD<sup>37</sup>; Rajat Vohra, MD<sup>37</sup>; Archana Paliwal, MD<sup>37</sup>; M.Pavan Kumar, MD<sup>38</sup>; A.Bikshapathi Rao, MD<sup>38</sup>; Nyanthung Kikon, PGDPHM<sup>39</sup>; Rhondemo Kikon, MScIH<sup>40</sup>; K. Manohar, 36 MD<sup>41</sup>; Y.Sathyanarayana Raju, MD<sup>41</sup>; Arun Madharia, MS<sup>42</sup>; Jaya Chakravarty, MD<sup>43</sup>; Manaswi Chaubey, 37
- 38 MD<sup>43</sup>; Rajiv Kumar Bandaru, MD<sup>44</sup>; Mehdi Ali Mirza, DM<sup>44</sup>; Sushila Kataria, MD<sup>45</sup>; Pooja Sharma<sup>45</sup>;
- 39 Soumitra Ghosh, MD46; Avijit Hazra, MD46.
- 40 <sup>1</sup>Indian Council of Medical Research, New Delhi, India
- 41 <sup>2</sup> Postgraduate Institute of Medical Education & Research, Chandigarh, India
- 42 <sup>3</sup> Gandhi Medical College, Telangana, India
- 43 <sup>4</sup> All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India
- 44 <sup>5</sup> All Indian Institute of Medical Sciences, Raipur Chhattisgarh, India
- 45 <sup>6</sup> College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India
- 46 <sup>7</sup> Medical College, Kolkata, West Bengal, India
- 47 <sup>8</sup> Infectious Disease And Beliaghata Hospital, Kolkata, West Bengal, India
- 48 <sup>9</sup> Christian Medical College, Ludhiana, Punjab, India
- 49 <sup>10</sup> Smt. NHL, Municipal Medical College, Ahmedabad, Gujarat, India
- 50 <sup>11</sup> CIMS Hospital, Ahmedabad, India
- 51 <sup>12</sup> All India Institute Of Medical Sciences, Bhubaneswar, India
- 52 <sup>13</sup> All India Institute Of Medical Sciences, Bhopal, Madhya Pradesh, India
- 53 <sup>14</sup> National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India
- 54 <sup>15</sup> Medstar Health, Baltimore, Maryland, United States of America
- 55 <sup>16</sup> National Institute Of Mental Health And Neurosciences, Bangalore, Karnataka, India
- 56 10006 within a source of the neurrestation of the context of the c

- 57 <sup>18</sup> Shaheed Nirmal Mahato Medical College, Dhanbad, Jharkahnd, India
- 58 <sup>19</sup> RD Gardi Medical College, Ujjain, Madhya Pradesh, India
- <sup>20</sup> Hi Tech Medical College and Hospital, Bhubaneswar, India
- 60 <sup>21</sup> Dhiraj Hospital & Sumandeep Vidyapeeth, Vadodara, Ahmedabad, India
- 61 <sup>22</sup> Late BRK Memorial Medical College, Jagdalpur, Chhattisgarh, India
- 62 <sup>23</sup> Gandhi Medical College, Bhopal, Madhya Pradesh, India
- 63 <sup>24</sup> Institute of Medical Sciences & SUM Hospital, Siksha 'O' Anusandhan deemed to be University,
- 64 Bhubaneswar, India
- 65 <sup>25</sup> Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
- 66 <sup>26</sup> Government Institute of Medical Sciences, Noida, Uttar Pradesh, India
- 67 <sup>27</sup> GMERS Medical College Himmatnagar, Gujarat, India
- 68 <sup>28</sup> Gulbarga Institute of Medical Sciences, Kalburagi, Karnataka, India
- 69 <sup>29</sup> St. Johns Medical College, Bengaluru, Karnataka, India
- <sup>30</sup> S.P.Medical College, Bikaner, Rajasthan, India
- 71 <sup>31</sup> SMS Medical College, Jaipur, Rajasthan, India
- 72 <sup>32</sup> JN Medical College Aligarh Muslim University, Aligarh, Uttar Pradesh, India
- <sup>33</sup> North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya,
- 74 India
- 75 <sup>34</sup> Tata Medical Centre, Kolkata, West Bengal, India
- <sup>35</sup> Dr D Y Patil Medical college Hospital and Research centre, Pune, Maharashtra, India
- <sup>36</sup> King George Medical University, Lucknow, Uttar Pradesh, India
- 78 <sup>37</sup> Mahatma Gandhi Medical College, Jaipur, Rajasthan, India
- <sup>38</sup> Kakatiya Medical College, MGM Hospital Warangal, Telangana, India
- 80 <sup>39</sup> Department of Health & Family Welfare, Government of Nagaland, Nagaland, India
- 81 <sup>40</sup> Community Health Initiative, Nagaland, India
- 82 <sup>41</sup> Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
- 83 <sup>42</sup> ESI Hospital and Gayatri Hospital, Raipur, Chhattisgarh, India
- <sup>43</sup>Institute of Medical sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
- 85 <sup>44</sup> ESIC medical College, Sanathnagar, Hyderabad. India
- 86 <sup>45</sup> Medanta-The Medicity, Gurugram, Haryana, India
- 87 <sup>46</sup> Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal
- 88 89

93

- 90 \*Corresponding Author:
- 91 Dr. Samiran Panda
- 92 Email: samiranpanda.hq@icmr.gov.in
- 94 These authors have contributed equally to this work.

95 96 97 98	This work was supported by the Indian Council of Medical Research
99	
100	
101	
102	
103	
104	

- 104
- 105
- 106
- 107
- 108

#### 109 Abstract

110

Objectives: This study aims to describe the demographic and clinical profile and ascertain the
determinants of outcome among hospitalised COVID-19 adult patients enrolled in the National
Clinical Registry for COVID-19 (NCRC).

114

115 Methods: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data

116 of hospitalized COVID-19 patients enrolled in NCRC between 1<sup>st</sup> September 2020 to 26<sup>th</sup> October

- 117 2021 were examined.
- 118

Results: Analysis of 29,509 hospitalised, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; 119 120 male: 18752 (63.6%)] showed that 15678 (53.1%) had at least one comorbidity. Among 25715 121 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of 122 breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n=3957). Adjusted odds of 123 dying were significantly higher in age-group  $\geq 60$  years, males, with diabetes, chronic kidney diseases, 124 chronic liver disease, malignancy, and tuberculosis, presenting with dyspnea and neurological 125 symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% 126 CI: 4.6, 7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4, 0.7)] or two doses of anti-SARS CoV-2 127 vaccine [OR: 0.4 (95% CI: 0.3, 0.7)] were protected from in-hospital mortality.

128

129 Conclusions: WHO ordinal scale at admission is the most important independent predictor for in-

hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protectionagainst mortality.

132 Keywords: SARS-CoV2, mortality, risk factors, outcome, COVID-Vaccine

133

134 Figure 1: Comorbidity profile of patients, n=29509

135 HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus

136

137 Figure 2: Trends of selected drugs and oxygen requirements

- 138
- 139

#### 140 Introduction

Globally, and in India, the pandemic of SARS-CoV-2 have resulted in unprecedented morbidity and mortality with detrimental effect on healthcare systems and economies. As a response to the pandemic, the 'National Clinical Registry for COVID-19' was initiated by the Indian Council of Medical Research (ICMR) in September 2020, with a broad objective to collect good quality, realtime data for evidence-based decision making in clinical practice, public health program and policy.

146

147 Hospital mortality among COVID-19 patients has varied from 19-39% across various studies.<sup>1-6</sup> It has 148 been observed that men, elderly (>60 years of age), and those with comorbidity such as asthma, 149 pulmonary disease. tuberculosis. chronic obstructive pneumonia. diabetes mellitus, 150 hypertension, renal, hepatic, and cardiac diseases and individuals with history of smoking or 151 substance use, history of kidney transplant are at higher risk of developing severe disease or 152 progression to death. The factors associated with such outcomes have been varied; older age being 153 consistent among many populations while others varied amongst studies.<sup>1–8</sup>

154 Indian investigations have reported association of old age, presence of diabetes mellitus, presence of 155 severe acute respiratory infection, raised inflammatory markers including interleukin-6, ferritin, 156 lactate dehydrogenase and d-dimer with progression of COVID and/ or related in-hospital mortality<sup>9-</sup>

- <sup>12</sup>. Majority of these studies enrolled a small number of participants located at a single centre. Here,
- we present data from a large cohort of hospitalized COVID-19 patients from 42 hospitals across the country.

160 The aim of this analysis is to study the demographic profile, clinical characteristics, and outcomes
161 among hospitalised COVID-19 adult patients, enrolled in the National Clinical Registry for COVID162 19 (NCRC) and to ascertain the factors associated with predefined outcomes.

163

#### 164 Methods

The National Clinical Registry for COVID-19 (NCRC) is a platform for on-going prospective data 165 166 collection, developed and maintained by ICMR in collaboration with the Ministry of Health & Family 167 Welfare (MOHFW), Government of India, All India Institute of Medical Sciences, New Delhi (AIIMS) and the ICMR-National Institute of Medical Statistics (NIMS). The structure and protocol of 168 169 the registry are available in the public domain (https://www.icmr. gov.in/tab1ar1.html). A hub and 170 spoke model has been adopted for this registry. At the beginning, an expression of intent was invited 171 for participation in the registry network; willing hospitals were screened based on a site feasibility 172 matrix. A steering committee with subject experts guides the conduct of the registry and suggests 173 solutions to roadblocks, if any. A monitoring committee consisting of institutional principal 174 investigators oversees the progress of the registry and explores newer ideas and initiatives, to keep the 175 registry dynamic. The central implementation team at ICMR headquarters remains responsible for the 176 overall execution of the project.

177 Across the network of NCRC, participating hospitals recruited consecutive in-patients, who had 178 COVID-19 infection confirmed by real time- polymerase chain reaction (RT-PCR), Nucleic acid 179 amplification test (NAAT) or Rapid Antigen Test (RAT). Demographic, clinical and outcome data are 180 collected in an on-going manner by the NCRC network. A dedicated team at the respective sites is 181 responsible for data collection and data entry under the supervision of the institutional primary 182 investigator and the central implementation team at ICMR. All the researchers were trained by the 183 central implementation team at ICMR via an online platform. Regular refresher trainings are conducted in order to minimise errors, and to address the gaps created by change of personnel in the 184 185 teams.

Data is collected using a pre-structured case report form (CRF) and is entered into an electronic portal, which has been developed and is being maintained by the ICMR-NIMS, Delhi. The CRFs include socio-demographic information, symptom and comorbidity profile at the baseline, clinical examination findings at the time of admission and on alternate days during the course of hospital stay, results of laboratory investigations conducted as per treating physician and the outcomes of the hospital stay.

192 The database platform is hosted on a secure server and is audited by the National Informatics Centre 193 (NIC). Information contained in the database, the configuration of the information within the 194 database, as well as the database itself are fully encrypted. Every client-server data transfer is 195 encrypted through a valid certificate. Data loss is prevented by frequent backup runs.

#### 196 Data Analysis

197 Socio-demographic, clinical, laboratory and hospital outcome data were analysed; categorical data 198 presented as frequency and proportions and continuous data as mean (standard deviation) or median 199 (Inter-quartile range), as appropriate. Logistic regression model was used to determine the factors 200 associated with the outcome of the patients. For the purpose of outcome analysis, death was defined 201 as death due to any cause of a COVID-19 positive patient occurring during hospital stay. Patients who 202 were transferred to another hospital or left against medical advice were excluded from the outcome 203 analyses, though their baseline characteristics were analysed. Age, gender, body mass index, pre-204 existing comorbidities, lag between symptom onset and admission, laboratory parameters at 205 admission including lactate dehydrogenase (LDH), ferritin, d-dimer, C-reactive protein (CRP) and 206 neutrophil to lymphocyte ratio (NLR), severity assessment by WHO ordinal scale<sup>13</sup> and status of anti-207 covid19 vaccination were used as explanatory variables in univariate analysis. Chi Square test, t-test 208 or rank sum test was used to examine the association between explanatory variables and outcome, as 209 appropriate. The variables with significant association and those with known clinical or contextual 210 importance were included in the multivariate logistic regression model. As laboratory values were

available for a limited number of participants, separate models were used for each of the biomarkers.

- 212 Data analysis was carried out using STATA v14 (College Station, TX, US).
- 213 Ethical Aspects

Approval was obtained from the Central Ethics Committee for Human Research at ICMR as well as

- from the respective Institutional Ethics Committee of each of the participating centres. Considering
- the observational nature of the registry, and collection of anonymised data being done primarily from
- the routine case records of the patients, a waiver of consent was granted by the Ethics Committees.
- 218

#### 219 Results

We present here an analysis of 29,509 hospitalised COVID-19 patients over the age of 18 years who were enrolled in NCRC from 1<sup>st</sup> September 2020 till 26<sup>th</sup> October 2021. The mean  $\pm$  SD age of the study population was 51.1  $\pm$  16.2 years; men (51.1  $\pm$  16 years) being similar to that of women (51  $\pm$ 16.5 years). Almost three fourth of the participants were at 40 years of age or above and two-thirds of the study participants in this group were men. The mean  $\pm$  SD body mass index of the participants

was  $24.8 \pm 4.1$  kg/m<sup>2</sup>, with one-third of the participants being within normal range, while over 64%were obese or overweight. (Table 1) Four per cent of the enrolled study participants were health care

- 227 workers.
- 228

Table 1: Demographic, symptom and laboratory profile at the time of admission (n=29509)

Characteristic	Values
Age groups 18-39 year 40-59 year 60 year and above	7742 (26.2) 11664 (39.5) 10103 (34.2)
Gender Male Female Transgender	18752 (63.6) 10754 (36.4) 3 (0.01)
Patients who had taken at least one dose of anti- SARS CoV-2 vaccine, n=7438	909 (12.2)
<sup>#</sup> BMI, kg/m2, mean ± SD, n=12046 Underweight Normal Overweight Obese	$24.8 \pm 4.1$ 361 (3) 3863 (32.1) 2765 (22.9) 5057 (42)
Symptom onset to admission in days, Median (IQR)	4 (2,6)
Total bilirubin, mg/dL Median (IQR), n=15091	0.6 (0.4, 0.8)
Hemoglobin, g/dL (Mean ± SD), n= 18506	12.2 ± 2.2
WBC count (Cells /mm <sup>3</sup> ), Median (IQR), n=18171	7400 (5200, 11000)
Neutrophils, %, Median (IQR), n=16053	76.5 (65.5, 85)
Lymphocytes, %, Median (IQR), n= 15971	17 (10, 26.6)

Neutrophil to lymphocyte ratio (NLR), Median (IQR), n=15942	4.4 (2.5, 8.5)
Platelet count, 1000s/ml <sup>3</sup> Median (IQR), n=18089	212 (158, 278)
Ferritin, ng/mL, Median (IQR), n=7166	2059 (1019, 3192)
LDH, IU/L, Median (IQR), n=8515	400 (265, 649)
CRP, mg/dL, Median (IQR), n=9962	32 (7.7, 90.3)
IL-6, pg/mL Median (IQR), n=2192	17 (5.8, 53.3)
D-Dimer, mg/L, Median (IQR), n=8142	0.6 (0.3, 1.9)
WHO Ordinal scale <sup>##</sup> on day 1 of admission, n=26909 • 3 • 4 • 5 • 6 • 7	13860 (51.5) 9864 (36.7) 2580 (9.6) 526 (2) 79 (0.3)

#### 230 Values expressed in n (%) unless specified.

231 #(Underweight: <18.5 kg/m2, normal weight: 18.5-22.9 kg/m2, overweight: 23-24.9 kg/m2, obese: ≥25 kg/m2) Ref: 232 233 WHO expert consultation group. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet Public Health. 2004; 363 (9403):157-163.

#https://www.who.int/blueprint/priority-diseases/key-

234 235 action/COVID19 Treatment Trial Design Master Protocol synopsis Final 18022020.pdf

236

237 Of the 29509 patients enrolled, 3794 (12.9%) were asymptomatic at the time of admission and were 238 admitted due to conditions other than COVID-19 and later diagnosed to have COVID-19 or 239 developed COVID-19 during the course of hospitalisation. Among 25715 (87.1%) patients who were 240 admitted with symptoms, fever was the most common symptom (72.3%). Shortness of breath and dry 241 cough was recorded in 48.9% and 45.5% of patients, respectively. Some of the other symptoms were fatigue (20.7%), cough with sputum (14.5%), sore throat (13.5%), muscle ache (12.3%) and headache 242 243 (11.2%). (S1 Figure) Median haemoglobin, leucocytes count, neutrophils and lymphocytes were largely within normal 244

245 limits while the inflammatory markers were raised. (Table 1)

246 No comorbidities were present in 13831 (46.9%) patients; 15678 (53.1%) participants had at least one 247 comorbidity. Hypertension and diabetes mellitus were the commonest comorbidities reported among 248 32.4% and 26.2% of patients, respectively. Chronic cardiac disease and chronic kidney disease was 249 present among 5.7% and 3.6% of the study participants, respectively. Other diseases including 250 asthma, malignancy, chronic pulmonary disease, chronic liver disease, stroke, tuberculosis, chronic 251 neurological disease, rheumatologic disease, autoimmune disease, and haematological disorders, HIV 252 infection, Hepatitis B and Hepatitis C infection were each reported in less than 2% of patients. (Figure 253 1)

254 The most commonly used drugs were anticoagulants and steroids administered to 60.9% and 60% of patients, respectively. Doxycycline, ivermectin, remdesivir and azithromycin were the other 255

commonly used drugs, while hydroxychloroquine, oseltavimir, faviparavir, IL-6 inhibitors including
tocilizumab or itolizumab and convalescent plasma each was administered to less than 5% of patients.
More than half of the admitted patients (15922, 54%) required oxygen support during their hospital
course, while 2307 (7.8%) required mechanical ventilation. (S1 Table)

Figure 2 shows the monthly trend of selected therapies since the inception of the registry. A marked increase is noticeable in the use of steroid, oxygen supplementation and remdesivir in May 2021, coinciding with the 2nd wave of the pandemic in India dominated by the delta variant of SARS-CoV-2 infection. The use of hydroxychloquine considerably declined after September 2020, while the use of convalescent plasma has been low throughout.

- Outcome data on death or discharge were available for 27251 patients; 689 patients who left against medical advice and 1569 patients transferred to other hospitals were excluded from the outcome analysis. In-hospital deaths were reported in 3957 (14.5%) participants and 23294 (85.5%) were discharged. The median duration (IQR) of hospital stay among the study participants was 7 (5, 10) days; 7 (5, 10) days among those discharged and 6 (2, 10) days among those who expired (p= <0.001). Out of the 3957 patients who expired, 3418 (86.4%) died within first 14 days of hospital stay and 539 (13.6%) died after 14 days of hospital admission.
- 272 Table 2 shows the association of baseline factors with in-hospital mortality in univariate analysis. Age 273  $\geq$  40 year, male gender, comorbidities such as diabetes mellitus, hypertension, chronic cardiac 274 disease, chronic kidney disease, chronic liver disease, malignancy, and stroke, tuberculosis well as 275 respiratory (fast or difficult breathing) or neurological symptoms (altered sensorium or seizures) at 276 presentation and WHO ordinal scale of 4 and above were associated with higher mortality. Receipt of 277 at least one dose of anti- SARS CoV-2 vaccine was associated with lower mortality as compared to 278 the unvaccinated patients [114 (13.3%) vs. 1306 (21.9%), p< 0.001]. Median concentrations of 279 random blood sugar, NLR, LDH, Interleukin-6 (IL-6), CRP, and D-dimer were significantly higher 280 among the patients who died as compared to those who were discharged from hospital. (Table 3)
- 281 282
- Table 2: Proportional mortality among hospitalized COVID-19 patients

Characteristic	Mortality (%)	Odds ratio (95% CI)	P value
Age			
• 18-39 years (n=7169)	529 (7.4)	(Reference)	-
• 40-59 years (n=10760)	1455 (13.5)	2 (1.8,2.2)	< 0.001
• $60+$ years (n=9322)	1973 (21.2)	3.4 (3.0, 3.7)	< 0.001
Gender			
• Male (n=17240)	2613 (15.2)	1.2 (1.1, 1.2)	< 0.001
• Female (n=10008)	1344 (13.4)	(reference)	-
Vaccinated with Anti-SARS CoV-2 vaccine			
• Unvaccinated (n= 5964)	1306 (21.9)	(Reference)	
• Vaccinated with one dose (n=550)	85 (15.5)	0.7 (0.5, 0.8)	< 0.001
• Vaccinated with two doses (n=305)	29 (9.5)	0.4 (0.3, 0.6)	< 0.001
Diabetes Mellitus			
• Yes (n=7126)	1397 (19.6)	1.7 (1.6,1.8)	< 0.001

< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
-
0.26

283

\*P value calculated by bivariate logistic regression

## 284

Table 3: Median laboratory parameters among patients who died and those who survived

Laboratory Parameter	Median (IQR)	P Value	
Hemoglobin Median (IQR), g/dL			
• Among those who died (n=2160)	12 (10.1, 13.4)	< 0.001	
• Among survivors (n=15098)	12.5 (11.1, 13.8)		
Random Blood Sugar, Median (IQR)			
• Among those who died (n=980)	180 (132, 255)	< 0.001	
• Among the survivors (n=7003)	138 (105, 228)		
Neutrophil lymphocyte Ratio			
Median (IQR)			
• Among those who died (n=1762)	10.7 (6.1, 19)	< 0.001	
<ul> <li>Among survivors (n=13156)</li> </ul>	3.9 (2.3, 7.3)		
LDH Median (IQR), IU/L			
• Among those who died (n=1021)	690.6 (458, 959)	< 0.001	
• Among survivors (n=6962)	365 (248, 575)		
IL-6 Median (IQR), pg/mL			
• Among those who died (n=347)	59.2 (21, 180)	< 0.001	
• Among survivors (n=1711)	13 (4.7, 36.7)		
CRP Median (IQR), mg/dL			
• Among those who died (n=1231)	84.3 (39.6, 141.8)	< 0.001	
• Among survivors (n=8156)	25.1 (6.1, 78.6)		
D-Dimer Median (IQR), mg/L			
• Among those who died (n=1007)	1.6 (0.7, 5.9)	< 0.001	
• Among survivors (n=6658)	0.5 (0.3, 1.4)		
Symptom onset to admission			
• Among those who died (n=21382)	4 (2,6)	0.54	
• Among survivors (n=3502)	4 (2,6)		

285 \*p value calculated by rank sum test

286

On sub group analysis of patients with diabetes mellitus, malignancy, tuberculosis and those admitted with WHO ordinal scale 4 and above, mortality among vaccinated was significantly lower in each individual subgroup. Among patients with liver disease and kidney disease, though the mortality was lower among the vaccinated but the difference was not statistically significant (Not shown in table).

291 Factors that were significantly associated with mortality in univariate analysis and those which had 292 clinical relevance were considered in the multivariate logistic models. Odds of in-hospital mortality 293 was significantly and independently higher among patients  $\geq 40$  year, male gender, with diabetes 294 mellitus, chronic kidney diseases, chronic liver disease, malignancy, and tuberculosis, and those who 295 presented with dyspnoea or neurological symptoms, after being adjusted for other comorbidities such 296 as hypertension, chronic cardiac disease, stroke, severity at admission (WHO ordinal scale), and 297 vaccination status. WHO ordinal scale being 4 and above at admission carried the highest odds of 298 dving [5.6 (95% CI: 4.6, 7.0)]. Patients vaccinated with one and two doses of anti-SARS CoV-2 299 vaccine had significantly lower odds of dying [OR: 0.5 (95% CI: 0.4, 0.7) for one dose & OR: 0.4 300 (95% CI: 0.3, 0.7) for two doses]. (Table 4)

- 301
- **302** т

303

Table 4: Adjusted Hazards ratio Determinants of hospital deaths using logistic regression

	Model 1 (n=6159)
	Odds ratio (95% CI)
Age Categories	
• 18-39 years	(Reference)
• 40-59 years	1.3 (1.1, 1.6)
• 60 years and above	1.9 (1.6, 2.3)
Gender (Male)	1.3 (1.1, 1.5)
Vaccinated with Anti-SARS CoV-2 vaccine	
• One dose	0.5 (0.4, 0.7)
Two doses	0.4 (0.3, 0.7)
Diabetes Mellitus	1.4 (1.2, 1.6)
Hypertension	0.9 (0.8, 1.1)
Chronic Cardiac Disease	0.8 (0.6, 1.0)
Chronic Kidney Disease	2.8 (2.0, 3.7)
Chronic Liver Disease	2.4 (1.1, 5.2)
Malignancy	1.9 (1.2, 3.2)
Stroke	1.0 (0.5, 2.3)
Tuberculosis	3.0 (1.5, 6.1)
Shortness of breath or fast breathing	1.3 (1.1, 1.5)
Altered sensorium/ seizures	3.6 (2.4, 5.4)
WHO ordinal scale 4 and above at admission	5.6 (4.6, 7.0)

304

305 Data available for various baseline laboratory parameters at baseline were limited (as described in 306 table 3). Hence, separate models were tested for each of these parameters. The odds ratio for all 307 biomarkers including haemoglobin, LDH, IL-6, and CRP were statistically significant, but marginally 308 over 1. The odds of death increased by 1.1 for each unit rise in baseline values of NLR and D-dimer

309 separately [OR:1.1 95%CI: 1.1,1.1] after adjusting for age, comorbidities and severity of the illness at

- admission. The logistic regression models (Model 2 to 8) that included laboratory values are
- 311 presented as S2 Table. The area under the curve for ROC (AUC ROC) for NLR was 0.79 (95%CI:
- 0.78, 0.80 and 0.7 (0.68, 0.71). (S2 Figure) Considering the optimal cut-off for NLR as 6.67, both the
- sensitivity and specificity to classify in-hospital death was 72%; a cut-off of 0.82 mg/L for baseline
- **314** D-Dimer had a sensitivity and specificity 71% and 65%, respectively.
- 315

#### 316 Discussion

Our study includes data from 29509 hospitalised COVID-19 patients from 42 hospitals across the country. Apart from the often cited factors such as diabetes mellitus, male gender and advanced age, our study highlighted the association of other comorbidities such as chronic kidney disease, chronic liver disease, malignancy and tuberculosis with increased in-hospital mortality of COVID-19 patients in Indian settings. The importance of anti-SARS-CoV-2 vaccination in protecting against mortality

- 322 was also evident from our analysis.
- 323 More than half of our study participants had at least one co-morbidity, most common being 324 hypertension & diabetes mellitus. The proportion of COVID-19 in-patients having hypertension is 325 similar to the overall population level frequency of hypertension recorded among adult Indians. On 326 the contrary proportion diabetics seem to be much higher in this cohort than the national 327 average.<sup>13,14,15</sup> Multiple studies have confirmed that following SARS-CoV-2 infection, diabetics are 328 more likely to be hospitalised as compared to non-diabetics, especially if there is poor glycaemic 329 control. <sup>16</sup> Diabetes causes an inhibition in neutrophil chemotaxis, phagocytosis, and intracellular 330 destruction of microbes, thus offering efficient virus entry and decreased viral clearance.<sup>17</sup>
- 331 In our study, patients above 40 years of age had 1.3 times higher adjusted odds of dying than the 332 younger patients, which increased to 2.1 time with advanced age  $\geq 60$  year. Advanced age, especially 333  $\geq$  60 year, is an established independent risk factor for dying in COVID-19 patients, as shown in various studies across multiple countries since the onset of the pandemic.<sup>18,15</sup> However, the working 334 335 age population above 40 years of age also have been deeply affected as shown in our investigation. It would be prudent to include them in all preventive measures and triaging strategies for severity. Age-336 337 standardized mortalities for COVID-19 in India, analysed from the Integrated Disease Surveillance 338 Programme special surveillance data, showed that along with the elderly above 60 years of age, the 339 age group of 45-59 years were also affected. <sup>20</sup> This could be partly explained by the fact that forced 340 expiratory volume is generally seen to decline after the age of 30-40 years.<sup>21</sup> Additionally, older age 341 group is known to have a higher prevalence of chronic diseases, which could further attenuate the 342 already dysregulated immune response.

Studies from various parts of India and the world have reported co-morbidities in various
 combinations to be associated with in-patient mortality in COVID-19 patients.<sup>16,173,24,25,26</sup>. Along with
 the more recognized risk factors such as diabetes mellitus, chronic kidney disease, and malignancy,

our investigation unearthed the independent association of chronic liver disease with higher odds of dying among COVID-19 in-patients. Another retrospective analysis from a single centre in South India linked chronic liver disease with in-hospital mortality of Covid-19 patients.<sup>27</sup> Increased systemic inflammation, immune dysfunction, coagulopathy and intestine dysbiosis are the hypothesised mechanisms. Important to note in this context is that, the pandemic has been associated with poor eating habits and increased alcohol intake, which might lead to an increase in severity of liver diseases.<sup>8,18,19,29</sup>

Presence of tuberculosis (on-treatment TB) was an important factor associated with higher in-hospital mortality in our cohort. This finding carries a significant relevance in a high TB burden country like India. Increased severity and mortality have been reported in COVID-19 patients with tuberculosis in two metanalyses which included only 26 and 34 Indian patients, respectively <sup>30,20</sup>. Our study provides more robust supportive evidence for association of present tuberculosis status withCOVID-19 mortality.

Severity of illness at admission as evident by presenting complaints of respiratory or neurological symptoms and WHO ordinal scale 4 or above had higher odds of dying in our registry participants. Similar observations have been reported from a few single centre studies from India, where majority of non-survivors required early oxygen supplementation (oxygen requirement is at WHO ordinal scale 4 and above)<sup>22,23</sup>.

364 The baseline laboratory markers including neutrophil-lymphocyte ratio (NLR), LDH, D-Dimer, IL-6 365 and CRP were higher among the non-survivors, though on multivariate analysis, the odds ratio was 366 marginally above one with minimal clinical relevance, except for NLR and D-dimer. Previous studies 367 have shown that raised biomarkers such as IL-6, CRP, LDH, and NLR are associated with higher mortality.<sup>32-35</sup> Considering these markers are non-specific indicators of inflammation, the baseline 368 369 values of II-6, CRP or LDH seem to offer limited benefit in meaningful prediction of mortality. NLR 370 being a readily available marker can be used to prognosticate outcomes at admission as can D-Dimer. 371 However, guidelines for clinical management from other countries have also stated that there is no 372 consensus in the evidence supporting use of any of the inflammatory markers or D-dimer at baseline

373 to stratify the risk and decide therapeutics. <sup>36</sup>

Importantly, the current study underlined the protection provided by COVID-19 vaccination against
in-hospital mortality. COVID-19 vaccine, irrespective its type, reduced the odds of dying by 50%
with one dose and by 60% with two doses. Other smaller, single centre studies from both South and
North India have demonstrated the effectiveness of COVID-19 vaccination in reducing mortality.<sup>37,38</sup>
These findings along with mathematical modelling based projections<sup>39</sup> underscore the key role of
vaccine in mitigating the impact of COVID pandemic and managing the burden it poses on the

- healthcare system.
- 381
- 382

#### 383 Limitations

As this was a record-based study in hospitals maintaining paper-based records, the identification of symptoms, comorbidities, complications and laboratory parameters relied on the accuracy of the records maintained. Secondly, the patients who were transferred to other institutes or who had left against medical advice were not followed up and could not be included in mortality analysis as their outcomes were unknown.

- 389
- 390 *Strengths*

391 The current analysis from the National Clinical Registry for COVID-19, to the best of our knowledge,

is the largest widely representative to examine the association of demographic, clinical characteristics,

393 and laboratory parameters with mortality among hospitalised COVID-19 patients in India. This data

- 394 captures information from various geographical zones of India involving multiple centres.
- 395

### 396 Conclusion

397 The current investigation highlights the importance of age  $\geq 40$  years and comorbidities like chronic 398 liver disease, and tuberculosis as predictors of in-patient mortality along with the oft-reported risk 399 factors such as male gender, diabetes mellitus, chronic kidney disease, and baseline severity of illness. 400 WHO ordinal scale 4 and above was an important independent factor associated with in-patient 401 mortality. Interestingly, the baseline values of CRP, IL-6 and LDH offered little help in predicting the 402 outcome, though NLR and D-dimer can be used to classify in-hospital outcomes with a sensitivity and 403 specificity ranging from 65% to 72%. On an encouraging note, vaccination against COVID-19 404 clearly lowered the risk of dying from the disease and featured as an important armamentarium in our 405 fight against COVID-19 pandemic.

13

406

407

408

409

410

411

412

413

414

415

416	Author	statements
<b>TTO</b>	Author	statements

### 418 Author Contributions


SP is the guarantor. Study design, data analysis, data interpretation and manuscript writing team: AM, GK, AT, AB, TCB, PB, TDB, SM, AT, YR, MJ, JRK, AHP, SB, RJ, GRM, DS, VVR, BB, SP, AA. Monitoring and Conduct of the study: AM, GK, AT, LKS, PM, YP. Patient enrolment, conduct of study, clinical care and data collection: AB, TCB, PB, TDB, SM, AT, YR, MJ, JRK, AHP, SB, RJ, GDP, VS, KS, RM, VSA, MAM, DK, SS, SM, PKK, AK, AS, AP, SC, MD, TM, SC, BB, SRP, DM, SC, AA, DV, MT, NS, MP, SM, AD, KYL, MR, CGS, UKO, RRJ, AK, AP, AS, MP, LS, MR, ADS, LK, PP, ND, SD, JS, AM, LP, JPS, SS, VKK, AK, NY, RU, SS, AS, NNS, NMS, KR, HP, PRM, MKP, SS, AK, MP, MA, DP, VS, SA, RC, MR, ND, BKG, BK, JG, SB, AA, MS, NF, SP, VN, SC, SM, SKS, ST, PL, HD, AG, VK, NS, RV, AP, MPK, ABR, NK, RK, KM, YSR, AM, JC, MC, RKB, MAM, SK, PS, SG, AH. Sources of Funding The study was supported by the Indian Council of Medical Research, New Delhi. Conflict of interest disclosure AM, GK, AT, LKS, SP are employed by the Indian Council of Medical Research, the funding source of the study. AA was employed by the Indian Council of Medical research at the beginning of the study. No other author has declared any conflict of interest. 

453	Bibli	ography
454	1.	Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, García Aguado M, Romero R, Huang J, et al.
455		Clinical profile and predictors of in-hospital mortality among older patients hospitalised for
456		COVID-19. Age Ageing. 2021 Feb 26;50(2):326–34.
457	2.	Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital
458		Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open. 2020 Dec
459		1;3(12):e2029058.
460	3.	Gray WK, Navaratnam AV, Day J, Babu P, Mackinnon S, Adelaja I, et al. Variability in
461		COVID-19 in-hospital mortality rates between national health service trusts and regions in
462		England: A national observational study for the Getting It Right First Time Programme.
463		EClinicalMedicine. 2021 May;35:100859.
464	4.	Khamis F, Memish Z, Bahrani MA, Dowaiki SA, Pandak N, Bolushi ZA, et al. Prevalence and
465		predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. J Infect
466		Public Health. 2021 Jun;14(6):759–65.
467	5.	Ruscica M, Macchi C, Iodice S, Tersalvi G, Rota I, Ghidini S, et al. Prognostic parameters of in-
468		hospital mortality in COVID-19 patients-An Italian experience. Eur J Clin Invest. 2021
469		Sep;51(9).
470	6.	Sarfaraz S, Shaikh Q, Saleem SG, Rahim A, Herekar FF, Junejo S, et al. (2021) Determinants of
471		in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. PLoS ONE 16(5):
472		e0251754. https://doi.org/10.1371/journal.pone.0251754.
473	7.	Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, et al. Impact of chronic
474		liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA
475		study. PloS One. 2020;15(12):e0243700.
476	8.	Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of
477		30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Nov;73(5):1063–71.
478	9.	Mammen JJ, Kumar S, Thomas L, Kumar G, Zachariah A, Jeyaseelan L, et al. Factors
479		associated with mortality among moderate and severe patients with COVID-19 in India: a
480		secondary analysis of a randomised controlled trial. BMJ Open. 2021 Oct 4;11(10):e050571.
481	10.	Zodpey SP, Negandhi H, Kamal VK, Bhatnagar T, Ganeshkumar P, Athavale A, et al. (2021)
482		Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control
483		study, India, 2020. PLoS ONE 16(12): e0261529. https://doi.org/10.1371/journal.pone.0261529.


484 485 486 487	11.	Agarwal. Epidemiological determinants of COVID-19 infection and mortality: A study among patients presenting with severe acute respiratory illness during the pandemic in Bihar, India [Internet]. [cited 2022 Jan 17]. Available from: https://www.npmj.org/article.asp?issn=1117-1936;year=2020;volume=27;issue=4;spage=293;epage=301;aulast=Agarwal
488 489 490	12.	Mishra V, Burma AD, Das SK, Parivallal MB, Amudhan S, Rao GN. COVID-19-Hospitalized Patients in Karnataka: Survival and Stay Characteristics. Indian J Public Health. 2020 Jun;64(Supplement):S221–4.
491 492 493	13.	Ramakrishnan S, Zachariah G, Gupta K, Shivkumar Rao J, Mohanan PP, Venugopal K, et al. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart J. 2019 Jul 1;71(4):309–13.
494 495 496	14.	Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017 Aug;5(8):585–96.
497 498 499	15.	O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021 Feb;590(7844):140–5.
500 501	16.	Barman Roy D, Gupta V, Tomar S, Gupta G, Biswas A, Ranjan P, et al. Epidemiology and Risk Factors of COVID-19-Related Mortality. Cureus. 13(12):e20072.
502 503 504	17.	Padmaprakash KV, Vardhan V, Thareja S, Muthukrishnan J, Raman N, Ashta KK, et al. Clinical characteristics and clinical predictors of mortality in hospitalised patients of COVID 19 : An Indian study. Med J Armed Forces India. 2021 Jul;77(Suppl 2):S319–32.
505 506	18.	Wang Q, Davis PB, Xu R. COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States. EClinicalMedicine. 2020 Dec 22;31:100688.
507 508 509	19.	Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021 Mar 10;1–17.
510 511 512	20.	Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. J Med Virol. 2020 Jul 28;10.1002/jmv.26311.
513		

514

- 515 S1 Figure: Clinical characteristics of the study subjects at the baseline among the symptomatic
- 516 patients, n=25715
- 517 S2aFigure: ROC for baseline neutrophil-lymphocyte ratio classifying in-hospital outcomes.
- 518 S2bFigure: ROC for baseline D-Dimer levels classifying in-hospital outcomes.
- 519 S1 Table: Treatment profile during hospital stay, n=29509
- 520 S2 Table: Adjusted odds ratio for determinants of hospital deaths among hospitalised COVID-19
- 521 patients using logistic regression model
- 522 S1 File: supplement
- 523
- 524
- 525
- 526



# Figure 1



# Figure 2